Court upholds suspension of generic Plavix sales

Share this article:
A federal appeals court upheld an injunction putting a halt to Apotex’s sale of a generic version of the blockbuster heart drug Plavix, The Wall Street Journal reported. The US Court of Appeals for the Federal Circuit in Washington upheld an August injunction issued by the US District Court in Manhattan. The ruling marks a legal victory for Bristol-Myers Squibb and Sanofi-Aventis, marketers of Plavix. The appellate court ruling means that Canadian generics company Apotex may not resume selling a cheaper copycat version of Plavix in the US, pending the outcome of a patent rights trial set to begin in January. Apotex began selling generic Plavix in August despite the existence of a Sanofi US patent for Plavix that doesn’t expire until 2011. Apotex argued that the patent is invalid and unenforceable, a contention disputed by Bristol-Myers and Sanofi.
Share this article:

Email Newsletters

More in News

Sanofi tightens PCSK9 race, exceeds Q2 expectations

Sanofi tightens PCSK9 race, exceeds Q2 expectations

Sanofi and partner Regeneron attached a $67.5-million priority review voucher to their experimental cholesterol drug alirocumab, making for a tighter race with Amgen.

HHS shows how diabetes adds up

HHS shows how diabetes adds up

A 2005-to-2010 survey shows diabetics 65-and-up juggle at least four co-morbid conditions and five medications for them.

AstraZeneca beefs up respiratory portfolio

AstraZeneca beefs up respiratory portfolio

AstraZeneca has made an $875-million move to beef up its respiratory pipeline by making Almirall's lineup its own.